MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targeting KRAS, PIK3CD and BCL2

Journal of Pathology

Volumn 232, Issue 4, 2014, Pages 415-427

  Liao, Wen Ting ^a   Ye, Ya Ping ^a   Zhang, Nian Jie ^a   Li, Ting Ting ^a   Wang, Shu Yang ^a   Cui, Yan Mei ^a   Qi, Lu ^a   Wu, Ping ^a   Jiao, Hong Li ^a   Xie, Yi Jun ^a   Zhang, Chi ^a   Wang, Jun Xian ^a   Ding, Yan Qing ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

apoptosis; BCL2; colorectal cancer; KRAS; miR 30b; PIK3CD; proliferation

Indexed keywords

MICRORNA; MICRORNA 30B; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BCL2 ONCOGENE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE REPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; ONCOGENE K RAS; PATHOGENESIS; PIK3CD ONCOGENE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

APOPTOSIS; BCL2; COLORECTAL CANCER; KRAS; MIR-30B; PIK3CD; PROLIFERATION;

3' UNTRANSLATED REGIONS; ANIMALS; APOPTOSIS; BINDING SITES; CELL DIFFERENTIATION; CELL PROLIFERATION; COLORECTAL NEOPLASMS; COMPUTATIONAL BIOLOGY; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HCT116 CELLS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RAS PROTEINS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TUMOR BURDEN;

EID: 84893839105     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4309     Document Type: Article

References (58)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Migliore L, Migheli F, Spisni R, et al., Genetics, cytogenetics, and epigenetics of colorectal cancer. J Biomed Biotechnol 2011; 2011: 792362.
3. Fearon ER, Vogelstein B,. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767.
4. Samuels Y, Wang Z, Bardelli A, et al., High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554. (Pubitemid 38541907)
5. Baker SJ, Fearon ER, Nigro JM, et al., Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989; 244: 217-221. (Pubitemid 19110302)
6. Bodemann BO, White MA,. Ral GTPases and cancer: linchpin support of the tumorigenic platform. Nat Rev Cancer 2008; 8: 133-140. (Pubitemid 351187648)
7. Schubbert S, Shannon K, Bollag G,. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7: 295-308. (Pubitemid 46480970)
8. Bonfrate L, Altomare DF, Di Lena M, et al., MicroRNA in colorectal cancer: new perspectives for diagnosis, prognosis and treatment. J Gastrointest Liver Dis 2013; 22: 311-320.
9. Hrasovec S, Glavac D,. MicroRNAs as novel biomarkers in colorectal cancer. Front Genet 2012; 3: 180.
10. Bartel DP,. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
11. Slaby O, Svoboda M, Michalek J, et al., MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer 2009; 8: 102.
12. Xiong B, Cheng Y, Ma L, et al., MiR-21 regulates biological behavior through the PTEN/PI-3 K/Akt signaling pathway in human colorectal cancer cells. Int J Oncol 2013; 42: 219-228.
13. Asangani IA, Rasheed SA, Nikolova DA, et al., MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008; 27: 2128-2136. (Pubitemid 351485639)
14. Chen HY, Lin YM, Chung HC, et al., miR-103/107 promote metastasis of colorectal cancer by targeting the metastasis suppressors DAPK and KLF4. Cancer Res 2012; 72: 3631-3641.
15. Zhong M, Bian Z, Wu Z,. miR-30a suppresses cell migration and invasion through downregulation of PIK3CD in colorectal carcinoma. Cell Physiol Biochem 2013; 31: 209-218.
16. Baraniskin A, Birkenkamp-Demtroder K, Maghnouj A, et al., MiR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL. Carcinogenesis 2012; 33: 732-739.
17. Tanic M, Yanowsky K, Rodriguez-Antona C, et al., Deregulated miRNAs in hereditary breast cancer revealed a role for miR-30c in regulating KRAS oncogene. PLoS One 2012; 7: e38847.
18. Bao Y, Lin C, Ren J, et al., MicroRNA-384-5p regulates ischemia-induced cardioprotection by targeting phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit-δ (PI3K p110δ). Apoptosis 2013; 18: 260-270.
19. Kobayashi N, Uemura H, Nagahama K, et al., Identification of miR-30d as a novel prognostic maker of prostate cancer. Oncotarget 2012; 3: 1455-1471.
20. Jiang L, Lin C, Song L, et al., MicroRNA-30e* promotes human glioma cell invasiveness in an orthotopic xenotransplantation model by disrupting the NF-κB/IκBα negative feedback loop. J Clin Invest 2012; 122: 33-47.
21. Cummins JM, He Y, Leary RJ, et al., The colorectal microRNAome. Proc Natl Acad Sci USA 2006; 103: 3687-3692. (Pubitemid 43376616)
22. Slattery ML, Wolff E, Hoffman MD, et al., MicroRNAs and colon and rectal cancer: differential expression by tumor location and subtype. Genes Chromosomes Cancer 2011; 50: 196-206.
23. Mosakhani N, Sarhadi VK, Borze I, et al., MicroRNA profiling differentiates colorectal cancer according to KRAS status. Genes Chromosomes Cancer 2012; 51: 1-9.
24. Faltejskova P, Svoboda M, Srutova K, et al., Identification and functional screening of microRNAs highly deregulated in colorectal cancer. J Cell Mol Med 2012; 16: 2655-2666.
25. Schepeler T, Reinert JT, Ostenfeld MS, et al., Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 2008; 68: 6416-6424.
26. Liao WT, Wang X, Xu LH, et al., Centromere protein H is a novel prognostic marker for human non-small cell lung cancer progression and overall patient survival. Cancer 2009; 115: 1507-1517.
27. Liao WT, Jiang D, Yuan J, et al., HOXB7 as a prognostic factor and mediator of colorectal cancer progression. Clin Cancer Res 2011; 17: 3569-3578.
28. Ambros V., The functions of animal microRNAs. Nature 2004; 431: 350-355. (Pubitemid 39265675)
29. Calin GA, Croce CM,. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866. (Pubitemid 44629897)
30. Esquela-Kerscher A, Slack FJ,. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-269.
31. Zhai H, Ju J,. Implications of microRNAs in colorectal cancer development, diagnosis, prognosis, and therapeutics. Front Genet 2011; 2: ii, 00078.
32. Spizzo R, Nicoloso MS, Croce CM, et al., SnapShot: microRNAs in cancer. Cell 2009; 137: 586-586, e581.
33. Wellner U, Schubert J, Burk UC, et al., The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009; 11: 1487-1495.
34. Shao C, Yu Y, Yu L, et al., Amplification and up-regulation of microRNA-30b in oral squamous cell cancers. Arch Oral Biol 2012; 57: 1012-1017.
35. Lu Y, Ryan SL, Elliott DJ, et al., Amplification and overexpression of Hsa-miR-30b, Hsa-miR-30d and KHDRBS3 at 8q24.22-q24.23 in medulloblastoma. PloS One 2009; 4: e6159.
36. Gaziel-Sovran A, Segura MF, Di Micco R, et al., miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell 2011; 20: 104-118.
37. Ichikawa T, Sato F, Terasawa K, et al., Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells. PLoS One 2012; 7: e31422.
38. Wszolek MF, Rieger-Christ KM, Kenney PA, et al., A MicroRNA expression profile defining the invasive bladder tumor phenotype. Urol Oncol 2011; 29: 794-801, e791.
39. Wong TS, Liu XB, Wong BY, et al., Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res 2008; 14: 2588-2592.
40. Quintavalle C, Donnarumma E, Iaboni M, et al., Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in glioma cells. Oncogene 2013; 32: 4001-4008.
41. Knight MJ, Riffkin CD, Muscat AM, et al., Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells. Oncogene 2001; 20: 5789-5798. (Pubitemid 32937948)
42. Li Q, Dashwood WM, Zhong X, et al., Bcl-2 overexpression in PhIP-induced colon tumors: cloning of the rat Bcl-2 promoter and characterization of a pathway involving β-catenin, c-Myc and E2F1. Oncogene 2007; 26: 6194-6202. (Pubitemid 47414373)
43. Sun N, Meng Q, Tian A,. Expressions of the anti-apoptotic genes Bag-1 and Bcl-2 in colon cancer and their relationship. Am J Surg 2010; 200: 341-345.
44. Bos JL,. Ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-4689. (Pubitemid 19213607)
45. Andreyev HJ, Norman AR, Cunningham D, et al., Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001; 85: 692-696. (Pubitemid 32929467)
46. Volinia S, Calin GA, Liu CG, et al., A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-2261. (Pubitemid 43271657)
47. Felli N, Fontana L, Pelosi E, et al., MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci USA 2005; 102: 18081-18086. (Pubitemid 41798505)
48. Al-Kuraya K, Novotny H, Bavi P, et al., HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J Clin Pathol 2007; 60: 768-772. (Pubitemid 47056905)
49. Fromont G, Godet J, Peyret A, et al., 8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy. Hum Pathol 2013; 44: 1617-1623.
50. Hollox EJ, Barber JC, Brookes AJ, et al., Defensins and the dynamic genome: what we can learn from structural variation at human chromosome band 8p23.1. Genome Res 2008; 18: 1686-1697.
51. Aldred PM, Hollox EJ, Armour JA,. Copy number polymorphism and expression level variation of the human α-defensin genes DEFA1 and DEFA3. Hum Mol Genet 2005; 14: 2045-2052. (Pubitemid 41418040)
52. Obernosterer G, Leuschner PJ, Alenius M, et al., Post-transcriptional regulation of microRNA expression. RNA 2006; 12: 1161-1167. (Pubitemid 43990541)
53. Bos JL, Fearon ER, Hamilton SR, et al., Prevalence of ras gene mutations in human colorectal cancers. Nature 1987; 327: 293-297. (Pubitemid 17075079)
54. Davies H, Bignell GR, Cox C, et al., Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954. (Pubitemid 34716871)
55. Steelman LS, Chappell WH, Abrams SL, et al., Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany, NY) 2011; 3: 192-222.
56. Foukas LC, Berenjeno IM, Gray A, et al., Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc Natl Acad Sci USA 2010; 107: 11381-11386.
57. Jiang M, Milner J,. Bcl-2 constitutively suppresses p53-dependent apoptosis in colorectal cancer cells. Genes Dev 2003; 17: 832-837. (Pubitemid 36397371)
58. Pugazhenthi S, Nesterova A, Sable C, et al., Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem 2000; 275: 10761-10766. (Pubitemid 30212704)